NEWS
Researchers Uncover New Mechanism of Resistance to Melanoma Drug
Researchers have discovered a new way that melanoma cells may become resistant to treatment with vemurafenib (Zelboraf), a targeted therapy that has produced dramatic, if transitory, results for some patients with advanced disease. In some cases, the drug has caused tumors to shrink and even disappear, but the treatment invariably stops working. Read more > >
Survey of Oncologists Suggests Lack of Progress in Cancer Pain Management
Results show room for improvement in education, attitudes, and beliefs on cancer painTrial Confirms Efficacy of HPV Vaccine, Shows Cross-Protection
Cervarix protects against infections by HPV-16, -18, and four other strainsGenetic Study Yields Clues to Neuroendocrine Prostate Cancer
Researchers identify potential therapy for this aggressive disease
COMMENTARY
A Conversation With Dr. Mason Bond on Improving the Treatment of Patients with Ewing Sarcoma
Dr. Mason Bond of the University of British Columbia in Vancouver discusses the addition of a novel drug combination to standard therapy in patients younger than 50.
SCIENCE SNAPSHOTS
What is this? Click on the image to find out. 
IN DEPTH
Study Raises Concerns about Using Cancer Cell Lines to Test Drug Resistance
Authors say new models are needed for studying resistance to cancer drugs
Unexpected Complications: Treating Cancer during Pregnancy
Limited research suggests most children prenatally exposed to chemotherapy are healthy
Interpreting Risk: Direct-to-Consumer Genetic Testing
How accurately do lay consumers interpret genetic test results?
Featured Clinical Trial: Novel Combination Chemotherapy for Localized Ewing Sarcoma
Will additional chemotherapy improve survival of children and young adults with Ewing sarcoma?
UPDATES
FDA Update
- FDA Commissioner Revokes Approval of Bevacizumab for Metastatic Breast Cancer
- New Form of Asparaginase Approved to Treat Acute Lymphoblastic Leukemia
- Ruxolitinib Approved to Treat the Bone Marrow Disease Myelofibrosis
Notes
- National Cancer Advisory Board Will Meet Next Week
- Proposals Sought for Use of PLCO Data and Biospecimens
- Cyber-Seminar Will Address Systems Thinking to Solve Public Health Problems
- NCI Guide on Communicating Data to Lay Audiences Now Available
- Major League Baseball Limits Players' Use of Tobacco
- President Obama Encourages Smokers to Quit
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
